Results 1 to 10 of about 2,872 (143)

Selinexor in relapsed/refractory multiple myeloma [PDF]

Therapeutic Advances in Hematology, 2020
Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and ...
Joshua Richter, Ajai Chari, Shambavi Richard   +2 more
exaly   +6 more sources

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges [PDF]

Frontiers in Pharmacology
This article aims to review the current application status and research advancements of selinexor in the treatment of acute myeloid leukemia (AML). Selinexor, as the first oral selective inhibitor of nuclear export protein Exportin-1 (XPO1), inhibits the
Xiaochun Peng
exaly   +4 more sources

Single‐Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT‐035 Study [PDF]

eJHaem
Background Janus kinase inhibitors (JAKis), the current standard of care for myelofibrosis (MF), provide clinical benefit, but responses are frequently incomplete, non‐durable, and associated with cytopenias, underscoring the need for therapies with ...
Sebastian Grosicki, Habte Yimer, Rosa Ayala, Suning Chen, Hong Liu, Françoise Boyer, Paola Guglielmelli, Marco Brociner, Paolo Sportoletti, Gabor Mikala, Panagiotis Tsirigotis, Jin Zhang, Tomer Mark, Yi Chai, Andrea Ellero, Alessandro Lucchesi   +15 more
doaj   +2 more sources

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB

Translational Oncology, 2021
Across many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor.
Yosef Landesman, Daniel A Weiser, Bruce Pawel   +2 more
exaly   +3 more sources

A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming [PDF]

Journal of Translational Medicine
Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy with limited therapeutic options in the relapsed or refractory setting. Selinexor, a selective inhibitor of nuclear export targeting XPO1, has demonstrated clinical activity in ...
Wenqi Zhang, Lin Shi, Yan Li, Cuiying He, Shuixin Cui, Yueping Liu, Xiaoxiao Wang, Lihong Liu, Yuhuan Gao, Lanping Diao, Lili Wu, Yingzhen Yao, Yi Feng, Xiaolin Wu, Shaoning Yin, Weijing Li, Boning Song, Chen Huang   +17 more
doaj   +2 more sources

Overview of Ocular Side Effects of Selinexor [PDF]

Oncologist, 2021
Abstract Background The aim of this review is to elucidate the type and frequency of ocular adverse events associated with selinexor with a goal to quantify the occurrence of these events in our investigator-initiated trial.
Nagham Al-Zubidi, Jordi Rodón, David S Hong   +2 more
exaly   +3 more sources

XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma [PDF]

Frontiers in Oncology
PurposeThe temozolomide (TMZ) resistance mechanisms in MGMT-promoter methylated IDH wildtype glioblastoma (GBM) tumors are poorly known. This study aimed to identify potential modulators of TMZ resistance in methylated GBM cells.MethodsA genome-wide ...
Josephine A. Mapunda, Yuta Suzuki, Danielle Burgenske, Paul A. Decker, Lin Zhang, Jeanette E. Eckel-Passow, Jann N. Sarkaria, Gaspar J. Kitange   +7 more
doaj   +2 more sources

Selinexor: Targeting a novel pathway in multiple myeloma

eJHaem, 2023
Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson   +9 more
doaj   +3 more sources

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy [PDF]

Frontiers in Oncology
BackgroundSelinexor, a first-in-class, oral exportin-1 inhibitor, showed activity in penta-refractory multiple myeloma (MM) in early trial exploration; however, the side-effect profile of twice-weekly dosing led to hesitant incorporation into widespread ...
Muhamed Baljevic, Gary Schiller, Tomer M. Mark, Dane R. Van Domelen, Cristina Gasparetto   +4 more
doaj   +2 more sources

Quantification of Total and Unbound Selinexor Concentrations in Human Plasma by a Fully Validated Liquid Chromatography-Tandem Mass Spectrometry Method [PDF]

Pharmaceutics
Background/Objectives: Selinexor is a selective nuclear-export inhibitor approved for hematologic malignancies, characterized by extensive plasma protein binding (>95%). However, a validated analytical method to accurately measure the clinically relevant
Suhyun Lee, Seungwon Yang, Hyeonji Kim, Wang-Seob Shim, Eunseo Song, Seunghoon Han, Sung-Soo Park, Suein Choi, Sungpil Han, Sung Hwan Joo, Seok Jun Park, Beomjin Shin, Donghyun Kim, Hyeon Su Kim, Kyung-Tae Lee, Eun Kyoung Chung   +15 more
doaj   +2 more sources